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Abstract
Purpose of review The goal of this review was to provide an update on the prevention and
treatment options for invasive candidiasis (IC) in the neonatal intensive care unit (NICU)
and pediatric intensive care unit (PICU).
Recent findings Studies have further validated the use of fluconazole for IC prophylaxis
among high-risk patients in the NICU. It remains unclear if prophylaxis leads to resistance
development and the ideal dosage regimen is still not clear. Recent studies have been
published comparing caspofungin and micafungin to amphotericin B and illustrated similar
efficacy outcomes in the NICU. Micafungin now has approval from the United States Food

Vol.:(0123456789)

Antimicrobial Stewardship (M Stevens, Section Editor)
and Drug Administration (FDA) for use in infants < 4 months of age. Prophylactic strategies
in the PICU could include zinc and vitamin D. Anidulafungin has recent non-comparative
data supporting use in pediatric patients older than 1 month of age and also has a recent
FDA approval for use in children 1 month of age and older.
Summary Fluconazole prophylaxis remains a reasonable strategy in select NICU patients,
although further analyses of resistance and the optimal dosage regimen are needed. Echinocandins are potential therapeutic options for non-meningitis or urinary tract infections
in both the neonatal and pediatric population.

Introduction
Invasive candidiasis (IC) is a nosocomial infection
that occurs in the neonatal intensive care unit (NICU)
and the pediatric intensive care unit (PICU) [1]. While
molds like Aspergillus also occur, they are much less
common than Candida species [2]. The most common
pathogenic species is C. albicans, but non-albicans
Candida like C. Parapsilosis, C. tropicalis, and others
are frequent and regional differences in pathogenic
species have been described [3].
The categorization of “invasive” candidiasis typically
includes Candidemia, Candida meningitis, Candida
endocarditis, but usually does not include mucosal
candidiasis (e.g., oropharyngeal or vaginal candidiasis) [4]. Unique to the pediatric population, candidiasis of the urinary tract can be associated with poor
outcomes and central nervous system involvement is
commonly of concern [5]. Analyses of prophylactic
strategies may utilize colonization site cultures (e.g.,
respiratory and gastrointestinal tract) as a surrogate
for more severe disease, but treatment approaches
generally focus on the less common, but more severe
invasive candidiasis.
In 2010, IC was reported as 1.4 infections/1000 NICU
admissions overall (down from 3.6 in 1997), with
multifold higher rates reported in patients with birthweights < 1000 g and the highest in those < 750 g (23.8
infections/1000 NICU admissions in 2010, down from
82.7 in 1997) [6]. The reductions up to 2010 were
likely due to increased use of fluconazole prophylaxis
and decreased antimicrobial utilization, but a recent
study has described a leveling off in infection reduction from 2011 to 2018 [6, 7]. In the PICU, rates of IC
have been reported as 4.2 infections/100 admissions

of patients at least 7 days of age with at least a 3-day
admission [8]. A recent analysis reported a reduction
in infections in the PICU from 2011 to 2018 [7].
Invasive candidiasis is associated with high morbidity
and mortality, with mortality rates ranging from 10 to
28% for pediatric patients as a whole [3]. Mortality
rates in the NICU for IC are estimated to be around
20% and are inversely correlated with birthweight,
with reported mortality up to 50% in very low birthweight infants [3]. Among survivors, long-term neurodevelopmental complications can occur in 10–50%
of patients [3, 9]. Among severe sepsis patients in
the PICU, a multicenter database analysis reported
case fatalities for fungal infections of 25.9% in 2014.
This was higher than the 13.9% mortality for Klebsiella pneumoniae, which had the next highest mortality among non-viral pathogens [2]. Due to the severe
complications associated with IC, effective prevention strategies and optimal treatment strategies are
imperative.
The guidelines currently published for the treatment
of candidiasis with pediatric recommendations are
the European Society for Clinical Microbiology and
Infectious Diseases (ESCMID) and Infectious Diseases
Society of America (IDSA) guidelines published in
2012 and 2016, respectively [4, 10]. Some of the recommendations in the guidelines were based on minimal evidence and new data has been published since
the 2016 update. In this review, we aimed to discuss
recent publications and elucidate if or how these publications could impact the prevention and treatment
of IC in neonatal and pediatric intensive care units.
Table 1 provides a brief summary of the important

- Micafungin or caspofungin
may have similar efficacy
compared to amphotericin
B deoxycholate
- Micafungin now FDA
approved for infants less
than 4 months
- Resistance is uncommon,
and MIC differences within
the susceptible rage may
not predict efficacy
IDSA: could be considered in - Non-fluconazole prophylacICUs at institutions with
tic strategies like zinc and
high rates of IC (> 5%)
vitamin D may have a role
ESCMID: no evidence-based - Select populations in the
recommended, but flucona- PICU may receive various
zole could be considered
prophylactic regimens due
in high-risk patients (e.g.,
to their underlying condiabdominal surgery)
tions
- IDSA and ESCMID: echi- Minimal new data updates
nocandins preferred first
for treatment
line in patients over
- Anidulafungin received
3–4 months of age for IC
FDA approval in patients
treatment
1 month and older

- Continue with prior guideline recommendations

- Consider ensuring receipt
of zinc and vitamin D in
critically ill PICU patients
with risk factors for IC
- Target patients primarily
based on their underlying
disease state

- Echinocandins may be an
alternative first-line agent
- Echinocandins are still not
well studied for neonatal
CNS and urinary infections

- What dosages are best to
use in critically ill patients

- Should prophylaxis be used
at all in patients lacking
other risk factors
- Should primarily nonfungal prophylaxis be used
(e.g., bundles)

- Ideal amphotericin product
- Comparison of echinocandins to fluconazole
- Use of echinocandins or
liposomal amphotericin in
CNS/urinary diseases

NICU, neonatal intensive care unit; PICU, pediatric intensive care unit; IDSA, Infectious Diseases Society of America; IC, invasive candidiasis: ESCMID, European Society
for Clinical Microbiology and Infectious Diseases; CNS, central nervous system; FDA, United States Food and Drug Administration; PICU, pediatric intensive care unit

Candidiasis treatment in the
PICU

Antifungal prophylaxis in
the PICU

Candidiasis treatment in the
NICU

- Long-term safety of antifungal prophylaxis
- Efficacy of non-fluconazole
prophylaxis
- Potential for resistance
still not definitive
- Dosing unclear

IDSA: fluconazole twice
weekly if the patient
is < 1000 g and institution
has > 10% IC
ESCMID: same as IDSA, but
could consider risk stratification in centers with low
incidence
IDSA: amphotericin B deoxycholate (precautionary
use of lipid products) or
fluconazole; echinocandins
as salvage therapy
ESCMID: amphotericin B
deoxycholate or lipid products or fluconazole

Fluconazole prophylaxis in
the NICU or neonates
- Evidence does not clearly
- Prophylaxis is still a
indicate the development
reasonable option in select
of resistant C. albicans, but highest risk patients and/
C. tropicalis has reports of
or at centers with high
increasing resistance
rates of infections
- Colonization of M. furfura
may be impacted

Recommendations—last Major new data summary Potential practice impli- Unanswered questions
guideline update
cations

Patient population

Table 1  Summary of new data since publication of the previous guideline for antifungal use in the NICU and PICU
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Relevant anfungal US Food and Drug
Administraon approvals since 2004*
Prior to 2004:
•

Amphotericin B deoxycholate: While recommended, manufacturer package
inserts do not have pediatric indicaons included

•

Amphotericin B liposomal: approved for ages 1 month and older

•

Caspofungin: approved for adults

•

Fluconazole: approved for all ages

•

Voriconazole: approved for paents 12 years and older

2005: Micafungin approved in adults

2013: Added 4 months and older to label

2019: Added < 4 months of age to label

2006: Anidulafungin approved in adults

2013: Added 12 years and older to label

2020: Added 1 month and older to label

2006: Posaconazole oral formulaon approved in paents 13 years and older
2008: Caspofungin approved for ages 3 months to 17 years
2015: Isavuconazonium approved for adult paents
2019: Voriconazole approved for paents 2 months and older
*Approvals may only be for certain locaons of infecon (e.g., candidemia, meningis, urinary tract infecons)
Historical Food and Drug Administraon label histories available at: hps://www.accessdata.fda.gov/scripts/cder/daf/

Fig. 1  Relevant antifungal US Food and Drug Administration approvals since 2004. Approvals may only be for certain locations of infection (e.g., candidemia, meningitis, urinary tract infections) (Historical Food and Drug Administration label
histories available at: https://www.accessdata.fda.gov/scripts/cder/daf/).

new literature and the implications of that literature
on practice.

Antifungal utilization in the NICU and PICU
As with other medications, antifungals have historically been approved by the
Food and Drug Administration (FDA) for use in adults and then studies were
done in the pediatric and neonatal population to assess safety, pharmacokinetics, and efficacy. Figure 1 illustrates the dates of pediatric FDA approvals for
the systemic antifungals currently available in the United States since 2014.
Off-label antifungal use, either with off-label indications or age groups, is
common in pediatric and NICU patients, especially for salvage therapy. For
example, amphotericin B deoxycholate is a guideline-recommended treatment option that has been used for years, but current manufacturer package
inserts do not have data for use in pediatric patients [11].
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Fluconazole is the most common antifungal used in the neonatal population, with most of its utilization attributed to prophylaxis that may not
be consistent with guideline recommendations [12, 13]. The second highest antifungal utilized in the NICU population is amphotericin B, which
comes in the “conventional” or deoxycholate form (AmpB-D), a liposomal
form (AmpB-L), and a lipid complex form. Other agents like voriconazole
(available intravenously or orally), posaconazole (available intravenously or
orally), itraconazole, and recently approved isavuconazonium account for a
small proportion of utilization. Importantly, most utilization studies were
completed before some of these agents became available or labeled in the
pediatric population and thus utilization may have recently changed.
Antifungal utilization data specific to the PICU are difficult to discern, but
in the pediatric population as a whole, fluconazole use still predominates,
followed by echinocandins and voriconazole [12]. Importantly, echinocandins and voriconazole are used for prophylaxis in the hematologic/oncologic population and this may account for the bulk of their use in the PICU.
Amphotericin B products have significantly less use. Other antifungals are
used in this population, but still less compared to fluconazole and echinocandins. Antifungal drug information and clinical pearls are presented in Table 2.

Guideline recommendations for antifungal prophylaxis
in the NICU
The most recent 2016 guidelines suggest that antifungal prophylaxis in the
NICU can be effective at preventing IC and potentially mortality. The recommended regimen is a 3–6 mg/kg twice weekly dose of fluconazole for 6 weeks
only in patients < 1000 g in institutions with a high IC incidence rate (> 10%)
[4].
These recommendations were based on multiple randomized control trials
and observational studies illustrating general benefit in this high-risk population without apparent risks or resistance described. In Cochrane Database
meta-analyses prior to the 2016 guideline, antifungal prophylaxis (primarily
fluconazole) decreased IC and studies with higher initial rates of fungal infection (typically cited as > 10%) were more likely to have an impact [14, 15].
The commonly cited number needed to treat for benefit (NNTB) is approximately 11 in the NICU population based on an aggregate incidence of ~ 16%
in the control groups, but the NNTB would vary based on the initial institutional incidence rate. The meta-analyses prior to the 2016 guideline publication did not illustrate a significant reduction in mortality [14, 15]. Institutions
have also used more selective criteria such as patients < 750 g with central
lines or patients < 1500 g that required more than 3 days of broad-spectrum
antibiotics and still showed a successful reduction in infections without a
subsequent increase in IC in patients not receiving prophylaxis [16].

Doses utilized

Fluconazole
IV, tablet, suspension [10,
21, 56–58]

Amphotericin B (liposomal)
IV [53–55]

Vd: 0.38–3.99 L/kg
Neonatal CNS penetration
reported to be 40–90%13
Children CNS penetration is
poor
Excretion: urinary
T ½: 14.8 (5 to 82 h) in
neonates
11.9–48 h in children and
adults

Notable PK parameters

Likely place in therapy

Other Pearls

- Invasive candidiasis in the - Can give a test dose prior
neonatal population
to administration
- Infusion-related reactions
are common. Pre-medicate
with an NSAID/acetaminophen ± diphenhydramine
or hydrocortisone monotherapy 30 to 60 min prior
to drug administration.
Rigors can be treated with
meperidine
- Nephrotoxicity can
occur during treatment.
Adequate hydration and
monitoring of kidney
function are required.
Neonates are reported to
have less nephrotoxicity
than adults
Neonatal: 3–5 mg/kg qday
Vd: 0.1–0.16 L/kg
- Resistant Candida infec- Drug can have increased
(NON CNS)
CNS penetration: 1–3%
tions
terminal half-life due to
Children: 3–5 mg/kg qday
Excretion: urine and feces
- Empiric therapy for neutro- slow redistribution from
T ½: 6–23 h
penic patients
tissues
- Invasive Aspergillus
- Dosing is not interchangeable between traditional
and liposomal product
- Less infusion reactions and
nephrotoxicity compared
to traditional amphotericin
Neonatal: treatment:
Vd: 0.913 L/kg
- Prophylaxis
- Inhibits CYP 3A4, 2C9, and
12–25 mg/kg loading dose, CNS penetration: 50–90%
- Invasive candidiasis
2C19 enzymes
then 6–12 mg/kg qday
Excretion: urine
- Meningitis
- Candida krusei demonProphylaxis: 3–6 mg/kg/dose T ½: 20–50 h
- Urinary tract infections
strates intrinsic resistance
twice weekly
(dependent upon renal func- Can cause QT prolongation
Children: 6–12 mg/kg loadtion)
ing dose 3–12 mg/kg qday

Amphotericin B deoxycholate Neonatal: 1 mg /kg qday
IV [50–53]
Children: 0.25–0.5 mg/kg,
can be titrated to 1.5 mg/
kg qday

Drug

Table 2  Pertinent antifungal dosing, clinical pearls, and potential places in therapy

Antimicrobial Stewardship (M Stevens, Section Editor)

Notable PK parameters
Vd: oral: 287 L; IV: 261 L
CNS penetration: limited
data, thought to be poor
Excretion: feces 71%, 13%
urine
T ½: suspension: ~ 35 h
Tablets: 26 to 31 h
IV: ~ 27 h

Doses utilized
All data limited
Oral suspension:
infants ≥ 6 months
to < 2 years: initial dosing:
200 mg QID
2–6 years: initial dosing:
200 mg QID
Children 7–12 years: initial
dosing: 300 mg/dose QID
Oral delayed-release tablets:
children 7–12 years: initial
dosing: 200 mg/dose TID
IV: VERY LMITED DATA
Children ≤ 11 years:
6–10 mg/kg BID on day
1, followed by 6–10 mg/
kg daily (maximum dose
300 mg)

Drug

Posaconazole
IV, delayed-release tablet,
and suspension [59, 60]

Table 2  (continued)

- Aspergillus prophylaxis
- Maintenance and salvage
therapy for mucormycosis

Likely place in therapy
- Oral suspension has better
absorption with a high-fat
meal or if taken with an
acidic beverage
- Displays saturable absorption
- Tablet has more predictable absorption than liquid
suspension
- Trough goals are typically > 0.7 mg/L for
prophylaxis and 1 mg/L for
treatment
- Concentration recommended to be drawn on
day 7 of therapy
- Inhibits the CYP 3A4
enzyme

Other Pearls
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- Invasive Aspergillus
Vd: biphasic in children 2
- Salvage therapy for mold
to < 12 years 0.81 mL/
infections
kg (central) 2.2 mL/kg
(peripheral)12
CNS penetration: 68–100%
Non-linear kinetics (most
likely Michaelis–Menten)
Adults: 4.6 L/kg
Excretion: urine
T ½: dose dependent, steady
state reached on day 3
with loading dose and by
day 5–8 without

Neonatal: Limited data case
reports: IV: 12 to 20 mg/
kg/day divided every 8 to
12 h
Children 2 to < 12 years: IV:
9 mg/kg q12 h for 2 doses
on day 1 followed by IV:
8 mg/kg/dose every 12 h
or PO suspension 9 mg/kg
q12 h
Children ≥ 12
to ≤ 14 years: < 50 kg: IV
loading dose:9 mg/kg/dose
q12 h for 2 doses; followed
by 4 to 8 mg/kg q12 h
≥ 50 kg: IV loading dose:
6 mg/kg q12 h for 2 doses
followed by 3 to 4 mg/kg
q12 h
Oral maintenance: < 50 kg:
9 mg/kg/q12 h ≥ 50 kg:
200 mg every 12 h
Adolescents ≥ 15 years: IV:
loading dose: 6 mg/kg q12
h for 2 doses; followed by
3 to 4 mg/kg q12 h
Oral maintenance: < 40 kg:
100 mg q12 h ≥ 40 kg:
200 mg q12 h

Voriconazole
IV, tablet, and suspension
[60–63]

Likely place in therapy

Notable PK parameters

Doses utilized

Drug

Table 2  (continued)
- Can cause photopsia,
neurotoxicity, rash, QT
prolongation, hepatotoxicity, and nephrotoxicity (IV
product has a cyclodextrin
solvent, albeit debated
toxicity)
- Oral formulations have
erratic absorption and
need to be separated from
food. Switch to oral only
recommended after significant clinical improvement
- Trough level goals of
1–5.5 mg/L. Levels of
2–6 mg/L can be targeted
if CNS involvement
- Dose adjustments are nonlinear, meaning changes
in trough/AUC may not be
proportional to changes in
dosage
- Is a substrate for and
inhibits CYP 3A4, 2C9, and
2C19 enzymes

Other Pearls
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Neonatal: 4–10 mg/kg qday Vd: highly variable with age - Systemic candidiasis
Children: IV: 2–3 mg/kg qday CNS penetration: negligible - Prophylaxis
Primarily hepatic metabolism - Salvage therapy for AsperExcretion: primarily feces
gillus
T ½ 6.7–21 h

- Systemic candidiasis
- Salvage therapy for Aspergillus

Vd: unknown, non-linear
kinetics
CNS penetration: negligible
Excretion: 41% urine; feces
35%
T ½: terminal 40–50 h

Micafungin
IV [36••, 60, 61, 66–68]

Caspofungin
IV [60, 61]

- Invasive candidiasis

Vd: 30 to 50 L
CNS penetration: Negligible
Excretion: primarily feces
T ½: 40 to 50 h

Neonatal: Limited data based
off of pharmacokinetic
study
IV: 3 mg/kg once on day 1,
then 1.5 mg/kg qday15
Children: IV: 1.5–3 mg/
kg once on day 1, then
0.75–1.5 mg/kg qday (max
200 mg)
Neonatal: Limited data IV:
25 mg/m2 qday or 2 mg/
kg qday
Children: 70 mg/m2 qday on
day 1, then 50 mg/m2 qday

Likely place in therapy

Anidulafungin
IV [60, 61, 64, 65]

Notable PK parameters

Doses utilized

Drug

Table 2  (continued)

- AUC increased with either
renal or hepatic impairment
- Drug accumulates due to
non-linear kinetics
- Can cause chills and hypotension on infusion
- Monitor Liver function
tests periodically
- Monitor liver function tests
- Not routinely used for urinary tract infections
- Higher doses are often
needed for neonates and
younger children due to
pharmacokinetic differences
- Higher doses are needed for
CNS infections

- Monitor liver function
tests
- Not routinely used for
urinary tract infections

Other Pearls
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Recent publications related to antifungal prophylaxis
in the NICU
Since the publication of the 2016 guidelines, one pre-post implementation
study failed to find a reduction in IC when fluconazole 3 mg/kg/day twice
weekly was used for 4 weeks in patients born < 1000 g at an institution with
a baseline IC rate of 4.4% [17]. Two meta-analyses since the last guidelines,
which combined studies with different dosing schedules, were able to show
that overall fluconazole prophylaxis decreased IC-related mortality [18, 19].
These new data are generally confirmatory of previous recommendations for
fluconazole prophylaxis at institutions with high IC rates in high-risk patients.
New literature and secondary analyses of previous studies have attempted
to determine an optimal fluconazole prophylaxis dosing regimen, although
it is still controversial. Adult based prophylactic studies have suggested that
concentrations > 2 mcg/mL (typically an AUC of 50 mcg*h/L) are ideal for
prophylaxis. Some Candida species have minimum inhibitory concentrations
of 4 mcg/mL. Two population pharmacokinetic monitoring studies have
illustrated that 3 mg/kg twice weekly would achieve troughs > MIC for most
Candida species, but 6 mg/kg twice weekly may be needed for Candida with
an MIC of 4 mcg/mL or above [20, 21]. Common Candida MICs at a given
institution should be taken into account when deciding on an institutional
fluconazole prophylaxis regimen.
When looking at clinical outcomes based on dosage, one meta-analysis
suggested that there was no difference in IC or overall mortality when comparing dosing regimens of 3, 4, or 6 mg/kg/dose administered twice weekly or
every 3 days, although 6 mg/kg/dose was considered better for the mortality
benefit on sensitivity analyses performed by the authors [19]. The authors
overall recommended 3 mg/kg/dose as the best dose to minimize exposure
but still have an equal effect. A second meta-analysis from 2021, also including multiple dosing regimens, found that the mortality benefit seen in the
overall cohort was seen primarily in studies using the dosing regimen of
3 mg/kg/day every 3 days weeks 1 and 2 and increased over the next 3 weeks
to daily dosing during weeks 5 and 6 [18]. The ideal fluconazole prophylactic
dosing regimen remains unclear.
A large concern surrounding fluconazole prophylaxis is the potential for
resistance development and recent studies have attempted to answer this
question. A secondary analysis of a randomized study on fluconazole prophylaxis looked specifically at resistance development and found a higher MIC
among Candida colonization cultures after prophylaxis, although this MIC
was still in the susceptible range (median MIC of 1 mcg/mL) [22•]. Most of
the colonizing Candida obtained were C. albicans with C. parapsilosis being
the second most common. There were also no breakthrough infections with
fluconazole-resistant Candida in this study. In a secondary analysis of a prospective observational study regarding fungal infections in the NICU, none
of the three infants with resistant Candida isolates (2 C. albicans and 1 C.
glabrata out of a 110 patients) received fluconazole prophylaxis prior to the
infection [23]. A recent pre-post implementation study from Korea reported
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a non-significant increase in resistance within patients using a 3 mg/kg/dose
twice weekly in fluconazole-resistant C. Parapsilosis (0/3 resistant in the control group and 5/9 in the fluconazole group [17]. A randomized controlled
trial from India also reported no C. albicans infections with fluconazole resistance when prophylaxis was used, but 60% resistance among C. tropicalis (a
species not commonly seen in other studies) [24]. An additional study from
Taiwan also illustrated the potential for M. furfur colonization with 1 breakthrough infection in patients receiving prophylaxis versus minimal colonization and no infections in patients without prophylaxis [25]. Multiple studies
did not find evidence of future resistance problems with fluconazole prophylaxis, but regional differences in fungal infection pathogens and low sample
sizes preclude an accurate determination of the occurrence of fluconazole
resistance due to prophylaxis. Additionally, studies have not looked at the
impact of fluconazole prophylaxis on institutional or regional susceptibility
patterns for Candida species.

Guideline recommended treatment options for invasive
candidiasis in the NICU
The 2016 IDSA and 2012 ESCMID guidelines both recommend either fluconazole (if no prior fluconazole exposure) or amphotericin B for neonatal
IC treatment, with the IDSA guidelines recommending caution with the use
of the lipid/liposomal amphotericin B formulations in the neonatal population [4, 10]. These recommendations were based on small prospective studies
including 23 and 56 infants and a retrospective database study. The first study
compared AmpB-D and fluconazole (23 total patients) and found similar
treatment outcomes with a better safety profile in the fluconazole cohort [26].
The second study compared AmpB-D, AmpB-L, and amphotericin B colloidal
dispersion (an amphotericin B dosage form not currently being manufactured
in the USA) to treat bloodstream infections and found all formulations to be
effective (56 total patients) [27]. This study did not evaluate central nervous
system (CNS) infections, a common concern in neonates. A database study
found that among 730 patients with IC (65% with blood involvement, 21%
urine involvement, < 1% CNS, and 14% mixed), infants treated with lipid
formulations of Amphotericin B (including liposomal, lipid complex, and
colloidal dispersion) had higher mortality rates than infants treated with
fluconazole or AmpB-D after controlling for other factors. Overall group mortality was 19%, but was 29% in the AmpB lipid-treated patients [28].
Prior to the 2016 guideline publication, there was limited data for echinocandins in neonates. Micafungin was compared to AmpB-L in a prospective
study containing 14 patients where 7/7 (100%) patients in the micafungin
group vs 4/7 (57.1%) in the AmpB-L group had treatment success [29]. Caspofungin was compared to AmpB-D in 32 neonates with IC and demonstrated a
favorable response in 86.7% of patients compared to 41.7% (p-value = 0.04)
in the AmpB-D cohort [30]. Of note, only a total of 5 patients from both these
studies in the echinocandian cohorts had CNS infections, and echinocandins
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are reported to have poor penetration of the CNS (Table 2). There is a concern for nephrotoxicity when using AmpB-D; however, studies in the neonatal population have an acceptable toxicity profile with AmpB-D [27, 28].
Fluconazole is traditionally well tolerated, but has intrinsic resistance to C.
krusei and auris and can have variable resistance to C. glabrata and tropicalis
[31, 32]. With a continuing concern for resistance development over time, it
is important to evaluate alternative treatment options.

Recent publications related to treatment options for invasive
candidiasis in the NICU
Micafungin gained FDA approval for patients under 4 months of age in 2019
based on safety data from 168 patients accrued from 9 clinical trials (Fig. 1).
Although the label does include descriptions of 10 mg/kg/day or higher dosing specifically for patients with meningoencephalitis, the 4 mg/kg/day dose
was the approved dose and it is not indicated for patients with meningoencephalitis or ocular disease [33]. Caspofungin does not have FDA approval
for use in neonates/preterm infants < 3 months of age, and anidulafungin has
approval for patients 1 month of age and older [34, 35]. Recent prospective
studies have investigated the safety and efficacy of echinocandins as compared
to the traditional standard of care, AmpB-D, although both were terminated
early due to slow recruitment [36••, 37••].
A phase 3, randomized, double-blinded, parallel group, non-inferiority
study randomized infants from 3 to 120 days of life with a positive Candida
sp. culture to receive either micafungin 10 mg/kg/day or AmpB-D 1 mg/kg/
day [36••]. There were 20 patients included in the micafungin group (16
with candidemia and 7 with urinary tract involvement) and 10 in the AmpBD group (7 with candidemia and 1 with urinary tract involvement). Two
patients in the micafungin and one in the AmpB-D arm had CNS involvement
identified by the data review board. Fungal-free survival (FFS) was achieved
in 12 patients (60%) in the micafungin group compared to 7 (70%) in the
AmpB-D group. In a secondary analysis, there was a positive clinical response
on day 7 in 61% and 70% in the micafungin and AmpB-D groups. Persistent
fungal infections occurred in 2 (10%) of infants in the micafungin group
and 2 (20%) of the AmpB-D group, with C. parapsilosis, glabrata, and albicans
being responsible. Adverse events occurred in similar proportions for each
group, with 18 (90%) in the micafungin group and 9 (90%) in the AmpB-D
group experiencing a treatment-emergent adverse event. Bilirubin and hepatic
enzymes were elevated more in the micafungin group and electrolyte replacement and acute kidney injury (AKI) were higher in the AmpB-D group. A
pharmacokinetic analysis based on targets from animal models of Candida
meningoencephalitis, demonstrated a dose of 10 mg/kg/day of micafungin is
adequate for CNS disease while also being safely tolerated [36••].
A phase 2 randomized, multicenter, double-blind, comparator-controlled
study also compared caspofungin 2 mg/kg/day to AmpB-D 1 mg/kg/day
[37••]. The study enrolled 33 patients (1 with meningoencephalitis, 24 with
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candidemia) in the caspofungin arm and 16 in the AmpB-D arm (1 with
meningoencephalitis, 8 with candidemia). FFS, 71% and 68.8%, respectively,
was similar between the 2 groups. Two (6.5%) patients in the caspofungin
group had drug-related side effects versus 2 (12.5%) in the AmpB-D arm
[37••].
A multicenter, observational, prospective trial published in 2019 from
France investigated the safety and efficacy of micafungin in pediatric patients
[38]. This study enrolled a total of 29 non-hematologic neonates treated for
mostly probably IC, with only two neonates having confirmed IC (C. albicans
and C. glabrata). The investigators found micafungin to be effective in 28/29
(97%) of infants. The safety analysis in NICU patients found 4 adverse events
and none were considered to be related to the study drug. The mean dose
of micafungin in this study was 7.6 mg/kg/day. The authors concluded that
micafungin was well tolerated in neonates.
A secondary analysis of a prospective observational study described the
prevalence of Candida sp. resistant to AmpB-D, fluconazole, and micafungin
in infants with IC [23]. There were 110 infants that yielded a total of 308
Candida isolates with susceptibility data. The most common Candida sp. were
albicans (60%), parapsilosis (35%), and glabrata (3%). All isolates were found
to be susceptible to AmpB-D and micafungin; 3 were resistant to fluconazole.
There were 42% of included infants with a high MIC pathogen (defined above
the 90th percentile MIC of all isolates) to one of the three aforementioned
agents. Having this high MIC pathogen did not correlate with prior receipt
of fluconazole or nystatin prophylaxis and did not correlate with death rates,
neurodevelopment impairment, or a combined endpoint at 18–22 months
of age. While a subgroup analysis was not performed, it should be noted that
all of the 7 patients with a Candida MIC of ≥ 2 mcg/mL for fluconazole either
died or had neurodevelopmental impairment at 18–22 months. The study
authors concluded MIC elevations that are still considered susceptible may
not impact treatment outcomes, but the number of resistant isolates was
small. Thus, outcome differences and treatment options for patients harboring a Candida sp. with a fluconazole MIC ≥ 2 mcg/mL remain unclear.
The literature surrounding the safety and effectiveness of echinocandin
use in the NICU has increased since the publication of the 2016 guidelines
and may suggest the use of this class of antifungal agents in select patient
populations, although efficacy is still unclear in CNS disease. Alternative azole
antifungals aside from fluconazole have been used for salvage therapy or
non-candidal fungal infections (e.g., voriconazole for Aspergillus), but robust
safety and efficacy data in the neonatal population is very limited (Table 2).

Guideline recommended fungal prophylaxis in the pediatric
intensive care unit
In the 2016 guidelines for Adult ICUs, prophylaxis could be used in centers with > 5% IC rates in select high-risk patients. This verbiage does not
specifically state use in a PICU, although some institutions may use this as
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guidance to determine if prophylaxis may be needed [4]. Risk factors for IC
in the PICU identified via multivariable prediction models have included
length of PICU stay, receipt of parenteral nutrition, need for central venous
catheters, malignancy, thrombocytopenia, and broad-spectrum antibiotic
use (specifically vancomycin and anaerobic active agents for > 3 days) [8,
39]. Utilizing a combination of factors likely increases the sensitivity and
specificity of these predictive factors. The ideal risk factor or combination
of risk factors for IC has not been clearly elucidated, and thus, it can be
difficult to determine the high-risk patients who need prophylaxis and/or
treatment initiation [40]. It is important to note that many immunosuppressed patients or patients with chronic diseases predisposing them to
infections (e.g., malignancy, chronic granulomatous disease, solid organ,
or bone marrow transplant) may be receiving prophylactic antifungals as
part of management for their primary disease. These antifungals are usually
continued while in the PICU.
There is also no preferred agent for prophylaxis in PICU if it is to be
started [40]. In the 2016 guidelines for adult ICUs, fluconazole is offered
as a possible option with echinocandins as an alternative [4]. There is
a concern for increases in resistance and adverse events, and therefore,
prophylaxis with non-antifungal alternatives is commonly considered [41].
A prophylaxis method recommended in the 2016 guidelines for adult ICUs
is daily chlorhexidine baths to reduce the incidence of bacteremia and as
an end result also potentially reduce candidiasis, but other methods of
prevention are critical to study to help prevent candidiasis in the PICU [42].

Recent publications regarding prophylaxis in the PICU
Recent studies have investigated the use of additional non-antifungal
prophylaxis strategies to prevent and reduce the resistance of antifungal
drugs. A randomized, placebo-controlled trial including 724 children
(1–5 years old) assessed the efficacy of 20 mg elemental daily zinc (administered as a syrup) supplementation in patients admitted to the PICU.
Plasma zinc concentrations are often low in critically ill patients and zinc
has shown antimicrobial efficacy against C. albicans. Candidemia occurred
in 10 patients (2.8%) with zinc supplementation compared to 22 (6%) in
the placebo group (p = 0.03) [43•].
The same authors also studied the use of 300 IU vitamin D supplemented
yogurt drinks as an alternative prophylaxis measure for 416 PICU patients
(1–5 years of age) receiving broad-spectrum antibiotics for > 48 h. Candida
colonization, especially in the gastrointestinal tract, is believed to correlate
with higher incidences of IC and in vitro studies suggest vitamin D has fungicidal activity against C. albicans. Outcomes were measured 14 days after
initiation. Five patients (0.5%) in the vitamin D group had candidemia versus
14 (6.7%) in the placebo group (p = 0.02) [44]. These two strategies may be
simple non-antifungal-based methods to help decrease IC in the PICU.
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Guideline recommendations for treatment of invasive
candidiasis in the PICU
A wide array of patients are admitted to the PICU, including neonates and
some adults with chronic childhood diseases. In general, patients are admitted to the PICU for advanced life support such as intubation due to respiratory failure, vasopressor administration, or other forms of advanced life
support for hemodynamic compromise. Thus, antifungal use in the PICU is
likely focused on the treatment of candidal sepsis.
Prior to the publication of the 2016 guidelines, caspofungin and
micafungin had FDA approval for use in infants and children, but anidulafungin only had approval for patients > 16 years of age (Fig. 1). Although the
PICU population is not clearly defined in the 2016 candidiasis guidelines, the
guidelines recommend echinocandins for first line for treatment of IC in nonneutropenic and neutropenic patients and thus would likely be considered
first line in the PICU. Fluconazole is an option if the patient is not severely
ill and as step-down therapy. Amphotericin B products and voriconazole are
typically reserved for specific non-Candida infections or if there is resistance
[4]. Table 2 provides additional information regarding antifungals in the
pediatric population.

Recent publications related to the treatment of invasive
candidiasis in the PICU
Two recent meta-analyses including pediatric and some neonatal studies illustrated similar outcomes between echinocandins and amphotericin B products
possibly with less discontinuation of echinocandins due to side effects [45,
46]. A multicenter, observational, prospective trial from France included 14
PICU patients treated for potential IC (5 with proven IC) and illustrated effective outcomes in 12/14 patients (85.7%). One patient had hepatic lesions
which were deemed to have a possible relation to micafungin [38]. Significant
new comparative publications were not identified since the publication of
the 2016 guidelines.
Anidulafungin received FDA approval in 2020 for patients aged 1 month
and up for candidemia or intra-abdominal abscesses/peritonitis due to
Candida species, but not endocarditis, osteomyelitis, or meningitis (Fig. 1).
This labeling came from 2 open-label non-comparative studies involving
49 patients 2–18 years and 19 patients 1 month to 2 years and [47, 48••].
The study with patients 2–18 years had an all-cause mortality rate of 14.3%,
although only one death was likely due to IC with an overall global success
rate of 70.8%. Bacteremia was the most common IC (93.4% of the study
population) [47]. In the study with infants 1 month–2 years of age, 16 had
culture-confirmed IC with 15/16 having candidemia and one infection
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involving the urinary tract. Only one (5.3%) patient died during the study
and it was 40 days after enrollment. Global response success occurred in 11
patients (68.8%) [48••]. The authors concluded pediatric patients treated
with anidulafungin had a similar response to adults and pharmacokinetic
analyses achieved a similar drug response compared to adults. Due to the lack
of a comparative study, the labeling change primarily extrapolated efficacy
data from adult studies.
Overall the new data is not likely to significantly change IC treatment
options in the PICU. It is important to remember that PICU patients could
have renal or hepatic dysfunction and may require advanced life support
techniques, continuous renal replacement therapy (CRRT), and/or extracorporeal membrane oxygenation (ECMO), all of which may impact antifungal
drug dosing and selection. For example, patients in acute renal failure need
a dose reduction for fluconazole use since it is excreted largely unchanged
in the urine. Conversely, larger doses are needed in CRRT and ECMO due
to increased fluconazole elimination and increased volume of distribution,
respectively [49]. In these patients, the dosage and selection of antifungals
should be individualized based on pharmacokinetic and safety considerations
of both the drug and the patient.

Summary
Invasive candidiasis is a concerning cause of infections in the NICU and
PICU. Prophylaxis in NICU patients can be considered based on institutional IC rates and patient characteristics. The available evidence still has not
clearly illustrated detrimental resistance development to this strategy. But,
more data on the occurrence and relevance of antifungal resistance in institutions utilizing prophylaxis is needed. There are recent, albeit small sample
size, studies utilizing echinocandins that could impact the initial antifungal
treatment choice for IC in the NICU, and micafungin is now FDA approved
for use in patients less than 4 months of age. It remains difficult to determine
what PICU patients would benefit from antifungal prophylaxis, and strategies
aside from antifungal prophylaxis could be considered. Echinocandins likely
remain the primary treatment option for IC in PICU patients.
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